Induction of hepatic microsomal hydroxylative enzymes is an important aspect of detoxication of fat-soluble toxicants. The magnitude of induction depends on numerous factors, such as the nature and dose of toxicant as well as dietary factors. Research was conducted on (1) endrin tolerance in rats, (2) preliminary comparisons of inductive effects of various organochlorine pesticides in rats to select compounds for further study in guinea pigs, (3) general effects of various dietary factors on induction, and (4) effects of ascorbic acid deficiency on induction of hepatic microsomal hydroxylative enzymes by organochlorine pesticides in guinea pigs. Measurements were made of body weight gain, feed consumption, liver weight, in vivo and in vitroenzyme activities, and body levels of pesticides and vitamins. Tolerance developed in rats fed 25 ppm endrin in the diet. There was severe intoxication during the first week but complete recovery of rate of body weight gain and feed consumption occurred during the second week, in spite of continued ingestion of the endrin-containing diet. Induction of endrin-degrading microsomal enzymes was proposed as the mechanism for tolerance. Pretreatment with the potent inducer, dieldrin, diminished the severity of endrin intoxication. However, pretreatment with another inducer, phenobarbital, afforded less protection in proportion to the extent of microsomal enzyme induction. Organochlorine pesticides, tested for their inductive capacity in rats, in decreasing order of effectiveness then fed as 25 ppm of the diet for 15 days, were heptachlor epoxide, dieldrin, endrin, 1,1-Bis-(p-chlorophenyl)-2,2,2-Trichloroethane (DDT), Ovex, gamma-chlordane, and lindane. Of these, DDT and dieldrin were compared over the range of 1 to 50 ppm of the diet. Dieldrin was a more potent inducer at all dietary levels. At low doses both compounds produced greater induction when measured by hexobarbital sleep time than by the in vitro enzyme procedures. At high doses, the in vitro 0-ethyl 0-p-nitrophenyl phenyl-phosphonothioate (EPN) detoxication was a more responsive measure. Dieldrin, DDT, and lindane were fed to guinea pigs at 25 ppm of the diet for 15 days, but only dieldrin stimulated a significant level of induction. DDT antagonism of dieldrin storage seen in rats by Street (Sci. 146:1580, 1964) did not occur in guinea pigs, but rather dieldrin antagonized DDT storage. Some general dietary factors affecting induction in rats were observed. A semipurified diet lowered the baseline microsomal enzyme activity but supported induction as effectively as a conventional diet. Vitamin A at very high dietary levels induced enzyme activity; this induction was apparently additive to that produced by 1 ppm dieldrin. Other fat-soluble Vitamins produced inconsistent responses. Ascorbic acid deficiency in guinea pigs impaired induction by dieldrin. Impairment was seen by the second day on the deficient diet. However, dieldrin was able to produce a small amount of induction at all stages of deficiency. In frank scurvy, induction by DDT and lindane was completely blocked, but there was a moderate level of induction by dieldrin. Maintenance of maximum induction was related to dietary rather than liver levels of ascorbic acid; 50 ppm ascorbic acid in the diet was grossly inadequate while 200 ppm supported about 80% of the induction produced by feeding 2000 ppm. It was concluded that (1) microsomal enzyme induction is important in resistance to organochlorine intoxication, (2) factors found in the normal diet can induce microsomal enzyme activity, (3) high dietary levels of ascorbic acid are necessary to support maximum induction, and (4) dieldrin is an inducer of such high potency that it can stimulate a limited amount of induction in spite of ascorbic acid deficiency.

Indiana University-Purdue University Indianapolis (IUPUI) / Liver fibrosis is a common consequence of various chronic liver diseases. Although transforming growth factor β 1 (TGFβ1) expression is known to be associated with liver fibrosis, the reduced clinical efficacy of TGFβ1 inhibition or the inefficiency to completely prevent liver fibrosis in mice with liver-specific knockout of TGF receptor II suggests that other factors can mediate liver fibrogenesis. As a TGFβ superfamily ligand, activin A signaling modulates liver injury by prohibiting hepatocyte proliferation, mediating hepatocyte apoptosis, promoting Kupffer cell activation, and inducing hepatic stellate cell (HSC) activation in vitro. However, the mechanism of action and in vivo functional significance of activin A in liver fibrosis models remain uncertain. Moreover, whether activin B, another ligand structurally related to activin A, is involved in liver fibrogenesis is not yet known. This study aimed to investigate the role of activin A and B in liver fibrosis initiation and progression. The levels of hepatic and circulating activin B and A were analyzed in patients with various chronic liver diseases, including end-stage liver diseases (ESLD), non-alcoholic steatohepatitis (NASH), and alcoholic liver disease (ALD). In addition, their levels were measured in mouse carbon tetrachloride (CCl4), bile duct ligation (BDL), and ALD liver injury models. Mouse primary hepatocytes, RAW264.7 cells, and LX-2 cells were used as in vitro models of hepatocytes, macrophages, and HSCs, respectively. The specificity and potency of anti-activin B monoclonal antibody (mAb) and anti-activin A mAb were evaluated using Smad2/3 luciferase assay. Activin A, activin B, or their combination were immunologically inactivated by the neutralizing mAbs in mice with progressive or established liver fibrosis induced by CCl4 or with developing cholestatic liver fibrosis induced by BDL surgery. In patients with ESLD, NASH, and ALD, increases in hepatic and circulating activin B, but not activin A, were associated with liver fibrosis, irrespective of etiology. In mice with CCl4-, BDL-, or alcohol-induced liver injury, activin B was persistently elevated in the liver and circulation, whereas activin A showed only transient increases. Activin B was expressed and secreted mainly by the hepatocytes and other cells, including cholangiocytes, activated HSCs, and immune cells. Exogenous administration of activin B promoted hepatocyte injury, activated macrophages to release cytokines, and induced a pro-fibrotic expression profile and septa formation in HSCs. Co-treatment of activin A and B interdependently activated the chemokine (C-X-C motif) ligand 1 (CXCL1)/inducible nitric oxide synthase (iNOS) pathway in macrophages and additively upregulated connective tissue growth factor expression in HSCs. Activin B and A had redundant, unique, and interactive effects on the transcripts related to HSC activation. The neutralization of activin B attenuated the development of liver fibrosis and improved liver function in mice with CCl4- or BDL-induced liver fibrosis and largely reversed the already established liver fibrosis in the CCl4 mouse model. These effects were improved by the administration of additional anti-activin A antibody. Combination of both antibodies also inhibited hepatic and circulating inflammatory cytokine production in the BDL mouse model. In conclusion, activin B is a potential circulating biomarker and potent promotor of liver fibrosis. Its levels in the liver and circulation increase significantly in both acute and chronic states of liver injury. Activin B might additively or interdependently cooperate with activin A, which directly acts on multiple liver cell populations during liver injury and fibrosis, as the combination of both proteins increases pro-inflammatory and pro-fibrotic responses in vitro. In addition, the neutralization of both activin A and activin B in vivo enhances the preventive and reversible effects of liver injury and fibrosis compared to that when activin B alone is neutralized. Our data reveal a novel target of liver fibrosis and the mechanism of activin B-mediated initiation of this process by damaging hepatocytes and activating macrophages and HSCs. Our findings show that activin B promotes hepatic fibrogenesis, and that targeting of activin B has anti-inflammatory and anti-fibrotic effects, which ameliorate liver injury by preventing or regressing liver fibrosis. Antagonizing either activin B alone or in combination with activin A prevents and regresses liver fibrosis in multiple animal studies, paving way for future clinical studies.

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第19964号 / 医博第4154号 / 新制||医||1017(附属図書館) / 33060 / 京都大学大学院医学研究科医学専攻 / (主査)教授 柳田 素子, 教授 横出 正之, 教授 渡邊 直樹 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

No description available.

No description available.

Xenobiotics are plant derived compounds metabolized by phase I and II liver enzymes. Phase I enzymes increase, and phase II enzymes decrease, xenobiotic toxicity. Xenobiotics considered were ergotamine, associated with fescue toxicosis, and sulforaphane, a phase II inducer. Hypothesized responses in liver gene expression and enzyme activity due to exposure to these xenobiotics were tested. Polymorphic mice were gavaged with sulforaphane, ergotamine or control over four daily dosing periods (2, 5, 8 and 11 d), with at least 5 mice per treatment. Mice were killed and livers collected 24 h after last dosing. With ergotamine, expression of phase II genes catecholâ Oâ amine methyltransferase 1 (P = 0.009) on d 8, and glutathioneâ Sâ transferase (Gst) mu1 (Gstm1; P = 0.049) on d 11 was increased, and sulfotransferase 5a1 on d 11 decreased (P = 0.02). Sulforaphane increased expression of cytochrome P450 1a2 on d 5 (P = 0.02) and flavin containing monooxygenases 1 on d 11 (P = 0.002), both phase I genes. It also increased expression of a phase II gene transcription factor (P = 0.03) and quinone reductase 02 (P = 0.007) on d 5, and Gstm1 on d 8 (P = 0.04) and d 11 (P = 0.01). Moreover, sulforaphane treated mice had higher (P < 0.05) Gstm1 expression across days. Among enzymes, only sufloraphane treated mice had higher (P < 0.05) Gst activity. The increase in both Gstm1 expression and Gst activity indicate a consistent benefit of sufloraphane on phase II enzyme activity. / Master of Science

Introdução: Em relação ao fígado, a esteatose é a consequência mais comum do consumo abusivo do etanol e predispõe à doença hepática mais grave. Os mecanismos da doença hepática alcoólica não são plenamente conhecidos e as terapias são escassas. Os objetivos desta tese foram: 1) averiguar os efeitos do etanol no fígado, utilizando o zebrafish como modelo experimental; 2) avaliar o tratamento com o Lactobacillus rhamnosus GG (LGG) na esteatose hepática; 3) observar os efeitos do etanol e do tratamento com o LGG no comportamento do zebrafish. Métodos: Foram realizados três experimentos utilizando peixes zebrafish, adultos, wildtype. O primeiro experimento foi formado por dois grupos, Controle (C) e Etanol (E), com 52 animais em cada um. O grupo E foi exposto a 0,5% de etanol por quatro semanas. Foram conduzidas análises histológicas e moleculares dos genes il-1b, tnf-α, il-10, sirt1, adiponectina e adipor2 nos fígados dos animais. No 2°experimento foram avaliados quatro grupos: Controle (C), Probiótico (P), Etanol (E) e Probiótico + Etanol (P + E), com 220 animais respectivamente. Durante quatro semanas os grupos P + E e P foram alimentados com ração com o probiótico LGG e os grupos E e C com ração sem probiótico. Foram realizadas análises histológicas e morfométricas no tecido hepático, quantificações de lipídeos séricos e hepáticos. No 3° experimento, os grupos C, E, P e P+E foram formados (n=15 animais por grupo) e, após duas semanas, o comportamento dos animais foi analisado no teste open-tank com o programa ANYmaze ®. Resultados: No 1° experimento os animais do grupo E apresentaram intensa esteatose hepática, aumento de glicogênio plasmático associado às gotículas lipídicas, alterações no retículo endoplasmático rugoso e degeneração de canalículos biliares. Houve acentuação na expressão hepática de il-1b, tnf-α, sirt1 e do adipor2, indicando que o etanol desencadeou resposta inflamatória e de proteção hepática. No 2° experimento, o grupo E apresentou intensa esteatose após quatro semanas, ao contrário do grupo P + E. A morfometria celular mostrou um aumento de 14,8 vezes no tamanho dos hepatócitos do grupo E (4° semana) quando comparado com C (p <0,0001). Os triglicerídeos séricos diminuíram no grupo P + E em comparação com C, P (p <0,001) e E (p = 0,004). O colesterol sérico do grupo P diminuiu comparado aos grupos C e E na segunda semana (p = 0,002 e p = 0,007) e do grupo P + E diminuiu comparado aos grupos E e C (p<0,0001), na quarta semana. As concentrações de triglicerídeos hepáticos reduziram no grupo P + E na quarta semana em comparação com E (p = 0,006). No 3° experimento, os animais expostos ao etanol apresentaram menor ansiedade em relação ao novo ambiente, evidenciada pela maior exploração da área superior do aquário. O efeito desibinidor do etanol não foi significativamente atenuado pelo tratamento com o LGG. Conclusões: Os resultados do primeiro estudo indicaram que o etanol desencadeia uma série de eventos celulares e moleculares e que a inflamação desempenha papel significativo na esteatose hepática. No segundo, foi demonstrado que o tratamento com LGG diminuiu os níveis séricos de triglicerídeos e de colesterol, atenuando a esteatose hepática. O terceiro estudo mostrou que o etanol teve efeito significativo no comportamento do zebrafish, que não foi modificado pelo LGG. / Introduction: Regarding to the liver, hepatic steatosis is the most common consequence of abusive alcohol consumption and predisposes to more severe liver disease. The mechanisms of alcoholic liver disease are not fully known and therapies are scarce. The objectives of this thesis were: 1) to verify the effects of ethanol in the liver using the zebrafish as an experimental model; 2) to evaluate a treatment with the probiotic Lactobacillus rhamnosus GG (LGG) in hepatic steatosis; 3) to observe the effects of ethanol and treatment with LGG in zebrafish behavior. Methods: Three experiments were performed using zebrafish, adult, wildtype. For the 1st trial, two groups were formed: Control (C) and Ethanol (E), with 52 animals in each group. E group was exposed to 0.5% ethanol during four weeks. Histological and molecular analysis of genes il-1b, tnf-α, il-10, sirt1, adiponectin, and adipor2 were conducted in zebrafish livers. For the 2nd trial, four groups were evaluated: Control (C), Probiotic (P), Ethanol (E) and Probiotic + Ethanol (P + E). During four weeks, the P + E and P groups were fed with food supplemented with LGG and E and C groups received food without probiotic. Histological and morphometric analysis in liver tissue, measurements of serum and hepatic lipids were performed. In the 3rd trial, C, E, P and P + E groups were formed and after two weeks, the animals' behavior was analyzed in opentank test with ANYmaze ® program. Results: In the 1st trial, animals in E group developed severe liver steatosis and cell abnormalities were observed: increase of glycogen associated to lipid droplets, alterations in the rough endoplasmic reticulum, degeneration of biliary canaliculi with presence of myelin figures inside. Increased hepatic expression of il-1b, tnf-α, sirt1 and adipor2 possibly indicates that ethanol triggered both inflammatory and hepatic protection responses. In the 2nd trial, E group presented severe steatosis after four weeks, in contrast to the E + P group. Cell morphometry showed a 14.8 fold in hepatocytes size of E (4th week) compared to C group (p <0.0001). Serum triglycerides decreased in the P + E group compared with C, P (p <0.001) and E groups (p = 0.004). Serum cholesterol decreased in P group compared to C and E groups at second week (p = 0.002 and p = 0.007) and in E + P group decreased compared with E and C groups (p<0.0001) at fourth week. Liver triglycerides were reduced in the P + E group at the fourth week compared to E group (p = 0.006). In the 3rd trial, there was an alteration in the behavior of animals exposed to ethanol compared to that nonexposed, an effect not significantly attenuated by treatment with LGG. Conclusions: Results of the first study indicate that ethanol triggers a series of cellular and molecular events and inflammation plays a significant role in hepatic steatosis. Then, it was shown that treatment with LGG decreased serum levels of triglycerides and cholesterol, attenuating hepatic steatosis. The third study showed that the ethanol, but not LGG has a significant effect on zebrafish behavior.

Introdução: Em relação ao fígado, a esteatose é a consequência mais comum do consumo abusivo do etanol e predispõe à doença hepática mais grave. Os mecanismos da doença hepática alcoólica não são plenamente conhecidos e as terapias são escassas. Os objetivos desta tese foram: 1) averiguar os efeitos do etanol no fígado, utilizando o zebrafish como modelo experimental; 2) avaliar o tratamento com o Lactobacillus rhamnosus GG (LGG) na esteatose hepática; 3) observar os efeitos do etanol e do tratamento com o LGG no comportamento do zebrafish. Métodos: Foram realizados três experimentos utilizando peixes zebrafish, adultos, wildtype. O primeiro experimento foi formado por dois grupos, Controle (C) e Etanol (E), com 52 animais em cada um. O grupo E foi exposto a 0,5% de etanol por quatro semanas. Foram conduzidas análises histológicas e moleculares dos genes il-1b, tnf-α, il-10, sirt1, adiponectina e adipor2 nos fígados dos animais. No 2°experimento foram avaliados quatro grupos: Controle (C), Probiótico (P), Etanol (E) e Probiótico + Etanol (P + E), com 220 animais respectivamente. Durante quatro semanas os grupos P + E e P foram alimentados com ração com o probiótico LGG e os grupos E e C com ração sem probiótico. Foram realizadas análises histológicas e morfométricas no tecido hepático, quantificações de lipídeos séricos e hepáticos. No 3° experimento, os grupos C, E, P e P+E foram formados (n=15 animais por grupo) e, após duas semanas, o comportamento dos animais foi analisado no teste open-tank com o programa ANYmaze ®. Resultados: No 1° experimento os animais do grupo E apresentaram intensa esteatose hepática, aumento de glicogênio plasmático associado às gotículas lipídicas, alterações no retículo endoplasmático rugoso e degeneração de canalículos biliares. Houve acentuação na expressão hepática de il-1b, tnf-α, sirt1 e do adipor2, indicando que o etanol desencadeou resposta inflamatória e de proteção hepática. No 2° experimento, o grupo E apresentou intensa esteatose após quatro semanas, ao contrário do grupo P + E. A morfometria celular mostrou um aumento de 14,8 vezes no tamanho dos hepatócitos do grupo E (4° semana) quando comparado com C (p <0,0001). Os triglicerídeos séricos diminuíram no grupo P + E em comparação com C, P (p <0,001) e E (p = 0,004). O colesterol sérico do grupo P diminuiu comparado aos grupos C e E na segunda semana (p = 0,002 e p = 0,007) e do grupo P + E diminuiu comparado aos grupos E e C (p<0,0001), na quarta semana. As concentrações de triglicerídeos hepáticos reduziram no grupo P + E na quarta semana em comparação com E (p = 0,006). No 3° experimento, os animais expostos ao etanol apresentaram menor ansiedade em relação ao novo ambiente, evidenciada pela maior exploração da área superior do aquário. O efeito desibinidor do etanol não foi significativamente atenuado pelo tratamento com o LGG. Conclusões: Os resultados do primeiro estudo indicaram que o etanol desencadeia uma série de eventos celulares e moleculares e que a inflamação desempenha papel significativo na esteatose hepática. No segundo, foi demonstrado que o tratamento com LGG diminuiu os níveis séricos de triglicerídeos e de colesterol, atenuando a esteatose hepática. O terceiro estudo mostrou que o etanol teve efeito significativo no comportamento do zebrafish, que não foi modificado pelo LGG. / Introduction: Regarding to the liver, hepatic steatosis is the most common consequence of abusive alcohol consumption and predisposes to more severe liver disease. The mechanisms of alcoholic liver disease are not fully known and therapies are scarce. The objectives of this thesis were: 1) to verify the effects of ethanol in the liver using the zebrafish as an experimental model; 2) to evaluate a treatment with the probiotic Lactobacillus rhamnosus GG (LGG) in hepatic steatosis; 3) to observe the effects of ethanol and treatment with LGG in zebrafish behavior. Methods: Three experiments were performed using zebrafish, adult, wildtype. For the 1st trial, two groups were formed: Control (C) and Ethanol (E), with 52 animals in each group. E group was exposed to 0.5% ethanol during four weeks. Histological and molecular analysis of genes il-1b, tnf-α, il-10, sirt1, adiponectin, and adipor2 were conducted in zebrafish livers. For the 2nd trial, four groups were evaluated: Control (C), Probiotic (P), Ethanol (E) and Probiotic + Ethanol (P + E). During four weeks, the P + E and P groups were fed with food supplemented with LGG and E and C groups received food without probiotic. Histological and morphometric analysis in liver tissue, measurements of serum and hepatic lipids were performed. In the 3rd trial, C, E, P and P + E groups were formed and after two weeks, the animals' behavior was analyzed in opentank test with ANYmaze ® program. Results: In the 1st trial, animals in E group developed severe liver steatosis and cell abnormalities were observed: increase of glycogen associated to lipid droplets, alterations in the rough endoplasmic reticulum, degeneration of biliary canaliculi with presence of myelin figures inside. Increased hepatic expression of il-1b, tnf-α, sirt1 and adipor2 possibly indicates that ethanol triggered both inflammatory and hepatic protection responses. In the 2nd trial, E group presented severe steatosis after four weeks, in contrast to the E + P group. Cell morphometry showed a 14.8 fold in hepatocytes size of E (4th week) compared to C group (p <0.0001). Serum triglycerides decreased in the P + E group compared with C, P (p <0.001) and E groups (p = 0.004). Serum cholesterol decreased in P group compared to C and E groups at second week (p = 0.002 and p = 0.007) and in E + P group decreased compared with E and C groups (p<0.0001) at fourth week. Liver triglycerides were reduced in the P + E group at the fourth week compared to E group (p = 0.006). In the 3rd trial, there was an alteration in the behavior of animals exposed to ethanol compared to that nonexposed, an effect not significantly attenuated by treatment with LGG. Conclusions: Results of the first study indicate that ethanol triggers a series of cellular and molecular events and inflammation plays a significant role in hepatic steatosis. Then, it was shown that treatment with LGG decreased serum levels of triglycerides and cholesterol, attenuating hepatic steatosis. The third study showed that the ethanol, but not LGG has a significant effect on zebrafish behavior.

Introdução: Em relação ao fígado, a esteatose é a consequência mais comum do consumo abusivo do etanol e predispõe à doença hepática mais grave. Os mecanismos da doença hepática alcoólica não são plenamente conhecidos e as terapias são escassas. Os objetivos desta tese foram: 1) averiguar os efeitos do etanol no fígado, utilizando o zebrafish como modelo experimental; 2) avaliar o tratamento com o Lactobacillus rhamnosus GG (LGG) na esteatose hepática; 3) observar os efeitos do etanol e do tratamento com o LGG no comportamento do zebrafish. Métodos: Foram realizados três experimentos utilizando peixes zebrafish, adultos, wildtype. O primeiro experimento foi formado por dois grupos, Controle (C) e Etanol (E), com 52 animais em cada um. O grupo E foi exposto a 0,5% de etanol por quatro semanas. Foram conduzidas análises histológicas e moleculares dos genes il-1b, tnf-α, il-10, sirt1, adiponectina e adipor2 nos fígados dos animais. No 2°experimento foram avaliados quatro grupos: Controle (C), Probiótico (P), Etanol (E) e Probiótico + Etanol (P + E), com 220 animais respectivamente. Durante quatro semanas os grupos P + E e P foram alimentados com ração com o probiótico LGG e os grupos E e C com ração sem probiótico. Foram realizadas análises histológicas e morfométricas no tecido hepático, quantificações de lipídeos séricos e hepáticos. No 3° experimento, os grupos C, E, P e P+E foram formados (n=15 animais por grupo) e, após duas semanas, o comportamento dos animais foi analisado no teste open-tank com o programa ANYmaze ®. Resultados: No 1° experimento os animais do grupo E apresentaram intensa esteatose hepática, aumento de glicogênio plasmático associado às gotículas lipídicas, alterações no retículo endoplasmático rugoso e degeneração de canalículos biliares. Houve acentuação na expressão hepática de il-1b, tnf-α, sirt1 e do adipor2, indicando que o etanol desencadeou resposta inflamatória e de proteção hepática. No 2° experimento, o grupo E apresentou intensa esteatose após quatro semanas, ao contrário do grupo P + E. A morfometria celular mostrou um aumento de 14,8 vezes no tamanho dos hepatócitos do grupo E (4° semana) quando comparado com C (p <0,0001). Os triglicerídeos séricos diminuíram no grupo P + E em comparação com C, P (p <0,001) e E (p = 0,004). O colesterol sérico do grupo P diminuiu comparado aos grupos C e E na segunda semana (p = 0,002 e p = 0,007) e do grupo P + E diminuiu comparado aos grupos E e C (p<0,0001), na quarta semana. As concentrações de triglicerídeos hepáticos reduziram no grupo P + E na quarta semana em comparação com E (p = 0,006). No 3° experimento, os animais expostos ao etanol apresentaram menor ansiedade em relação ao novo ambiente, evidenciada pela maior exploração da área superior do aquário. O efeito desibinidor do etanol não foi significativamente atenuado pelo tratamento com o LGG. Conclusões: Os resultados do primeiro estudo indicaram que o etanol desencadeia uma série de eventos celulares e moleculares e que a inflamação desempenha papel significativo na esteatose hepática. No segundo, foi demonstrado que o tratamento com LGG diminuiu os níveis séricos de triglicerídeos e de colesterol, atenuando a esteatose hepática. O terceiro estudo mostrou que o etanol teve efeito significativo no comportamento do zebrafish, que não foi modificado pelo LGG. / Introduction: Regarding to the liver, hepatic steatosis is the most common consequence of abusive alcohol consumption and predisposes to more severe liver disease. The mechanisms of alcoholic liver disease are not fully known and therapies are scarce. The objectives of this thesis were: 1) to verify the effects of ethanol in the liver using the zebrafish as an experimental model; 2) to evaluate a treatment with the probiotic Lactobacillus rhamnosus GG (LGG) in hepatic steatosis; 3) to observe the effects of ethanol and treatment with LGG in zebrafish behavior. Methods: Three experiments were performed using zebrafish, adult, wildtype. For the 1st trial, two groups were formed: Control (C) and Ethanol (E), with 52 animals in each group. E group was exposed to 0.5% ethanol during four weeks. Histological and molecular analysis of genes il-1b, tnf-α, il-10, sirt1, adiponectin, and adipor2 were conducted in zebrafish livers. For the 2nd trial, four groups were evaluated: Control (C), Probiotic (P), Ethanol (E) and Probiotic + Ethanol (P + E). During four weeks, the P + E and P groups were fed with food supplemented with LGG and E and C groups received food without probiotic. Histological and morphometric analysis in liver tissue, measurements of serum and hepatic lipids were performed. In the 3rd trial, C, E, P and P + E groups were formed and after two weeks, the animals' behavior was analyzed in opentank test with ANYmaze ® program. Results: In the 1st trial, animals in E group developed severe liver steatosis and cell abnormalities were observed: increase of glycogen associated to lipid droplets, alterations in the rough endoplasmic reticulum, degeneration of biliary canaliculi with presence of myelin figures inside. Increased hepatic expression of il-1b, tnf-α, sirt1 and adipor2 possibly indicates that ethanol triggered both inflammatory and hepatic protection responses. In the 2nd trial, E group presented severe steatosis after four weeks, in contrast to the E + P group. Cell morphometry showed a 14.8 fold in hepatocytes size of E (4th week) compared to C group (p <0.0001). Serum triglycerides decreased in the P + E group compared with C, P (p <0.001) and E groups (p = 0.004). Serum cholesterol decreased in P group compared to C and E groups at second week (p = 0.002 and p = 0.007) and in E + P group decreased compared with E and C groups (p<0.0001) at fourth week. Liver triglycerides were reduced in the P + E group at the fourth week compared to E group (p = 0.006). In the 3rd trial, there was an alteration in the behavior of animals exposed to ethanol compared to that nonexposed, an effect not significantly attenuated by treatment with LGG. Conclusions: Results of the first study indicate that ethanol triggers a series of cellular and molecular events and inflammation plays a significant role in hepatic steatosis. Then, it was shown that treatment with LGG decreased serum levels of triglycerides and cholesterol, attenuating hepatic steatosis. The third study showed that the ethanol, but not LGG has a significant effect on zebrafish behavior.

Submitted by (edna.saturno@ufrpe.br) on 2016-11-07T11:52:37Z No. of bitstreams: 1 Silvio Henrique de Freitas.pdf: 2034085 bytes, checksum: 9dab230ef672cfd4c52fed67b3c04de3 (MD5) / Made available in DSpace on 2016-11-07T11:52:37Z (GMT). No. of bitstreams: 1 Silvio Henrique de Freitas.pdf: 2034085 bytes, checksum: 9dab230ef672cfd4c52fed67b3c04de3 (MD5) Previous issue date: 2003-07-09 / Experimental models of hepatic ischemia have been very widespread. The Pringle maneuver, i.e. clamping by vascular tongs of the artery, vein and hepatic duct, and of the portal vein is used in many of these models. These models are used for studies in liver transplants. One of the complications in this maneuver is the splanchic congestion. This study has as objective the observation of the changes that occur in the spleen due to the ischemia produced by the clamping of the hepatic peduncle. For this 36 male mice were divided into four groups with 9 animals each. The Sham (S) group was not submitted to ischemia, and the groups E1, E2 and E3 were submitted to the Pringle maneuver for 10, 20 and 30 minutes, respectively. After these periods, fragments of the spleen were taken, fixed in formaldehyde and processed for inclusion in paraffin. The slits were dyed with Haematoxylin and Eosin and with Ferric-ferrocyanide. The results showed microscopic alterations in groups E2 and E3. There was intense vascular congestion, hemosiderin granules, decrease in the white pulp (lymphatic nodules and periarterial sheaths) and intense hemocateresis around the splenic sine curves, being these changes more intense at 30 minutes. In this group there was an accentuated digestion of red blood cells with the presence of hemosiderin granules. The data obtained permit us to conclude that at 20 minutes signs of spleen congestion begin and that at 30 minutes there is decrease in splenic parenchyma and increase in concentrations of ferric pigments. / Modelos experimentais de isquemia hepática têm sido muito difundidos. A manobra de Pringle, ou seja, o clampeamento por pinça vascular da artéria, veia e ducto hepático e da veia porta, é utilizado em muitos desses modelos. Esses modelos são utilizados para estudos em transplantes hepáticos. Uma das complicações dessa manobra é a congestão esplâncnica. Este trabalho tem como objetivo observar as alterações que ocorrem no baço frente a isquemia produzida pelo clampeamento do pedículo hepático. Para tanto foram utilizados 36 ratos machos, divididos em quatro grupos de 9 animais cada. O grupo Sham (S) não foi submetido a isquemia, já os grupos E1, E2 e E3 foram submetidos a manobra de Pringle por 10, 20 e 30 minutos respectivamente. Após esses períodos, fragmentos do baço foram retirados, fixados em formaldeído e processados para inclusão em parafina. Os cortes foram corados pela Hematoxilina e Eosina e pelo Ferrocianeto-Férrico. Nossos resultados mostraram alterações microscópicas nos grupos E2 e E3, onde notou-se intensa congestão vascular, grânulos de hemossiderina, diminuição da polpa branca (nódulos linfáticos e bainha periarteriais) e intensa hemocaterese ao redor dos sinusóides esplênicos, sendo essas alterações mais intensa aos 30 minutos. Neste grupo ocorreu uma acentuada digestão de hemácias com presença de grânulos de hemossiderina. Os dados obtidos permitiram concluir que aos 20 minutos já começa haver sinais de congestão esplênica, e que aos 30 minutos diminuição do seu parênquima esplênico e aumento da concentração de pigmentos de ferro.